Researchers have discovered that non pathogenic gut bacteria, including E. coli, encode and deploy type III secretion systems (T3SS)—microscopic syringe like structures previously thought exclusive to pathogens.
Your gut is not a peaceful place. Beneath the surface of every healthy gut microbiome, a vast microbial population has been quietly running an injection apparatus that scientists always assumed belonged to pathogens alone.
Researchers at Helmholtz Munich, together with collaborators at UMC Utrecht, Aix Marseille University, and Inserm, have found that non-pathogenic gut bacteria encode and deploy type III secretion systems — microscopic syringe-like structures that fire bacterial proteins directly into human cells. The finding, published Jan. 26, 2026 in Nature Microbiology, upends a long-standing assumption in microbiology: that these injection rigs are a pathogen specialty, not a commensal capability.
We have known for decades that bacteria such as Salmonella use T3SS to colonize human tissue and subvert immune responses. What Young, Dohai, and their colleagues discovered is that harmless gut bacteria — especially Escherichia coli and related Gammaproteobacteria — have the same machinery. Of 568 cultured Pseudomonadota genomes screened, 79 percent had complete T3SS. Among 16,179 gut metagenome-assembled genomes, 5 percent carried the full system. Nearly 60 percent of people in an Israeli cohort and 47 percent in a Dutch cohort harbored T3SS-positive strains at clinically meaningful abundance.
The bigger question was always what those molecular syringes were firing into human cells. To find out, the team mapped 1,263 interactions between 289 bacterial effectors and 430 human proteins — a wiring diagram of microbe-host communication that had never been drawn at this scale. The injected proteins landed squarely on immune signaling: the NF-kB pathway and cytokine responses including TNF, the target of widely used anti-inflammatory drugs.
In cell line experiments, eight effectors significantly modulated NF-kB activity — five activating it, three inhibiting it. That bidirectional effect is telling. These bacteria are not uniformly pro-inflammatory. They are negotiating with the immune system in both directions.
Crucially, the commensal effectors share almost nothing in sequence with their pathogenic cousins. Only 0.5 percent of strain effectors and 3 percent of meta-effectors showed high sequence similarity to known pathogen proteins. These are not repurposed virulence factors. They are a separate molecular vocabulary that commensals evolved to talk to human cells.
The researchers also looked at disease context. Effector genes were enriched in the gut microbiomes of Crohn's disease patients but depleted in ulcerative colitis patients — opposite patterns suggesting the same machinery may play distinct roles in each condition. "This fundamentally changes our view of commensal bacteria," said Prof. Pascal Falter-Braun, director of the Institute for Network Biology at Helmholtz Munich and corresponding author. "It shows that these non-pathogenic bacteria are not just passive residents but can actively manipulate human cells by injecting their proteins into our cells." The work also involved researchers at UMC Utrecht; Marianne Boes, a researcher there, said the injected bacterial factors "modulate the production of immune mediators by epithelial cells, that can directly influence intestinal health."
The clinical connection is suggestive but early. The functional work here is in cell lines, not human tissue, and the disease associations are correlative. Whether T3SS-mediated effector delivery contributes to inflammatory bowel disease or is a consequence of it remains an open question.
That caveat is doing real work in this paper, though. Most microbiome research to date has produced correlations: certain bacteria are more common in Crohn's, or in type 2 diabetes, or in depression. Finding the actual molecular apparatus — the specific proteins, the specific human targets, the specific pathway — is what moves this from pattern-watching to mechanism. That is the step the field has been stuck on.
It also raises a deeper evolutionary question. Did pathogens steal T3SS from commensals, or did commensals acquire it from pathogens? The paper's authors lean toward the latter — the distinct effector sequences suggest separate evolutionary histories rather than a simple theft. Either way, the same basic structure, the needle-and-syringe injection apparatus, ends up in both friendly and hostile bacteria. That is a satisfying biological irony.
Future work will need to move from cell lines to primary tissues and organoids, and from association to causation. If specific effectors can be linked definitively to Crohn's or ulcerative colitis, the therapeutic implications are significant: designer probiotics engineered to modulate specific immune pathways, or small molecules that block particular bacterial-human protein interactions. That is years away and speculative. The paper is careful to say so.
But the core finding is solid and stands on its own: the healthy human gut contains bacteria that actively communicate with human immune cells by injecting proteins into them, using the same molecular hardware that pathogens use — but for entirely different purposes. The microbiome is not a passive passenger. It has opinions.
Source: Young et al., Nature Microbiology, Jan. 26, 2026 — https://www.nature.com/articles/s41564-025-02241-y | Helmholtz Munich press release — https://www.helmholtz-munich.de/en/newsroom/news-all/artikel/more-than-just-gut-cohabitants-how-gut-bacteria-control-immune-responses